Harvard Men's Health Watch

Immunotherapy: A new option for advanced prostate cancer

Most prostate cancers respond well to androgen-deprivation therapy; prostate specific antigen (PSA) levels plummet, tumors shrink, and symptoms of the disease improve. The response can last for years but virtually all prostate cancers eventually escape androgen-deprivation therapy and sharply increasing a man chances of dying from prostate cancer. A new immunotherapy option, Provenge (sipuleucel-T) is now available. The new prostate cancer "vaccine" aims to rev up the body's own immunologic defense mechanisms so they will target androgen-independent prostate cancer cells.
To continue reading this article, you must login.
  • Research health conditions
  • Check your symptoms
  • Prepare for a doctor's visit or test
  • Find the best treatments and procedures for you
  • Explore options for better nutrition and exercise
Learn more about the many benefits and features of joining Harvard Health Online »